期刊文献+

VEGF和DLL4在婴幼儿血管瘤组织中的表达及相关性 被引量:6

Expression of VEGF and DLL4 in Infantile Hemangioma Tissue and Correlation of Them
下载PDF
导出
摘要 目的探讨VEGF及DLL4在婴幼儿血管瘤发生、发展过程中的作用机制。方法应用免疫组织化学SP法检测50例婴幼儿血管瘤(增生期26例,消退期24例)组织中VEGF,DLL4和FⅧRAg的表达水平。采用HPIAS-1000图文报告管理系统对VEGF和DLL4的表达进行定量分析。结果增生期组VEGF的表达明显高于消退期组和正常皮肤组(P<0.05),而后两组比较差异无统计学意义(P>0.05)。增生期组DLL4的表达明显高于消退期组和正常皮肤组(P<0.05),而后两组比较差异无统计学意义(P>0.05)。结论 VEGF和DLL4在增生期血管瘤组织中高表达,两者的表达具有明显的一致性,共同促进血管瘤内皮细胞的增殖,在血管瘤的发生、发展过程中起了重要的促进作用。 Objective To discuss the mechanism of DLL4 and VEGF in the development of infantile hemangioma.Methods The expression of VEGF,DLL4 and FⅧRAg in 50 cases of infantile hemangioma were detected by immumohistochemistry assay. Results The expression levels of VEGF in proliferating phase were significantly higher than involuting phase and normal skin tissue( P〈 0. 05),and the difference between the latter two groups was not statistically significant( P〉 0. 05). The expression levels of DLL4 of proliferating phase were significantly higher than involuting phase and normal skin tissue( P〈 0. 05),and the difference between the latter two groups was not statistically significant( P〉 0. 05). Conclusion The expression of VEGF and DLL4 was highly expressed in the proliferative hemangioma,and had obvious consistency. They also promoted the proliferation of vascular endothelial cells,played an important role in the development of hemangioma.
出处 《中国皮肤性病学杂志》 CAS CSCD 北大核心 2016年第3期225-227,232,共4页 The Chinese Journal of Dermatovenereology
基金 广东省医学科学技术研究基金(No.A2012286) 广东省科学技术厅(No.2013B021800191)
关键词 DLL4 VEGF 婴幼儿血管瘤 免疫组织化学 DLL4 VEGF Infantile hemangioma Immunohistochemistry
  • 相关文献

参考文献9

  • 1Kontomanolis E, Panteliadou M, Giatromanolaki A, et al. Deha-like ligand 4 ( DLIA ) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis [ J]. Med Oncol, 2014, 31 (5) : 945.
  • 2Wang H, Huang X, Zhang J, et al. The expression of VEGF and DlI4/ Notch pathway molecules in ovarian cancer[J]. Clin Chim Acta, 2014, 436 : 243 - 248.
  • 3Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives[J]. Cancer Lett,2012, 320(2) : 130 -137.
  • 4Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for canc- er: reassessing the target[J]. Cancer Res,2012,72(8) : 1909 - 1914.
  • 5Lei Shuisheng, Tu Yating, Zhang Duanlian, et al. Inhibition of heman- gioma endothelial cell proliferation by antisense oligonucleotides targe- ting to the mRNA encoding vascular endothelial growth factor[J]. Acta Med Univ Sci Technol Huazhong,2007,36(3 ) :336 -340.
  • 6Benedito R, Hellstrom M. Notch as a hub for signaling in angiogenesis [J]. Exp Cell Res, 2013, 319(9) : 1281 - 1288.
  • 7Phng LK, Gerhardt H. Angiogenesis : a team effort coordinated by notch [J]. Dev Cell, 2009, 16(2) : 196 -208.
  • 8Jin Y, Kaluza D, Jakobsson L. VEGF, Notch and TGFbeta/BMPs in regulation of sprouting angiogenesis and vascular patterning [J]. Bio- chem Soc Trans,2014, 42(6) : 1576 - 1583.
  • 9Kuhnert F, Kirshner JR, Thurston G. Dll4-Noteh signaling as a thera- peutic target in tumor angiogenesis [J]. Vase Cell,2011, 3 (1) : 20.

同被引文献48

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部